Stanford researchers have developed a new therapeutic approach to protect neurons and promote axon regeneration by restoring mitochondrial transport within axons, a key process disrupted in many neurodegenerative diseases.
Stanford researchers have developed an innovative, integrated diagnostic and therapeutic focused ultrasound (FUS) platform that non-invasively targets peripheral nerves to produce temporary, reversible nerve blockade for acute and chronic pain management.
Stanford researchers at the Chichilnisky lab have patented an artificial retina framework for dynamic electrical stimulation to improve the performance of electronic visual implants.
Stanford Artificial Retina Project researchers have developed an ASIC Retina Chip that interfaces with retinal ganglion cells to restore vision in patients with retinal degeneration.
Stanford researchers have developed EphrinA3 technology to strengthen epithelial barriers by increasing expression of cell-cell adhesion molecules, particularly desmoglein-1 (DSG1) and desmocollin-1 (DSC1).
Oral mucositis (OM) is a painful side effect of chemoradiotherapy, especially in children and adolescents, with a high incidence rate of over 20%-40% and up to 90% in high risk patients.
The Stanford team developed a versatile injectable alginate-collagen hydrogel, a significant advancement in regenerative medicine and targeted therapeutic delivery.
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
Stanford researchers have developed an advanced method for accurately tracking and accumulating radiation dose in magnetic resonance-guided radiotherapy.
Researchers at Stanford University have identified EP300 modulators as effective treatments for reducing skin scarring, demonstrating significant regeneration of hair follicles, sweat glands, and connective tissue architecture.
Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene
Stanford researchers in Prof. Corinne Beinat's lab have developed a small molecule radiotheranostic for targeted radionuclide therapy of cancers overexpressing system xc-, such as high-grade glioma and non-small cell lung cancer (NSCLC).
Of the 1.4 million first time mothers giving vaginal birth in the United States, approximately 75% will experience tearing of their vagina or perineum.
Researchers in the Airan Lab have developed a noninvasive method using low intensity transcranial ultrasound to drive cerebrospinal fluid (CSF) glymphatic and lymphatic flow to clear brain injury waste products from CSF and brain interstitium.